Table 1

Clinical characteristics and MYD88 L265P status of 20 patients with anti-MAG PN

Sex (M/F)Age MYD88 L265P mutationB-cell clonality testingPercentage bone marrow infiltration based on histologyPercentage bone marrow infiltration based on flow cytometry*Serum IgM level (g/L)Titrated MAG level above 1500 if available (BTU)†Subjective duration of disease (years)‡EMG-based duration of disease (years)‡
M64NegativeNegativeNegativeNegative1.7n.t.00
M67NegativeNegativeNegativeNegative2.3n.t.88
M76NegativeNegativeNegativeNegative8.1>700010
F66NegativeNegativeNegative<1%5.4>70 00010
M62NegativeNegativeNegativen.t.4>70 00010
M73NegativeNegativeNegativeNegative2.3n.t.111
F72NegativePositive<5%n.t.9>700030
M71NegativePositiveNegative1%5.7>70 00064
M72PositiveNegativen.t.<3>70 00010
F43Positive<5%n.t.7>70 000110
M70PositiveNegativen.t.<3>700043
F74PositiveNegativen.t.<3>70 000115
M62Positive<10%n.t.10>70 000124
M71Positive25n.t.3>70 00010
M66PositiveNegative2%5>70 000269
M64Positive<5%3%16n.t.116
F79PositiveNegative4%5.7n.t.1313
F59PositiveNegativen.t.4.7n.t.55
F75Positive<10%5%3.16n.t.40
M70Positive2%Negative0.6n.t.31
  • *While bone marrow histology was performed in all cases, additional flow cytometry of the bone marrow was available in a subset of 11 cases.

  • †While all patients had an anti-MAG titre of at least 1500 BTU, additional titration above that level was available for a subset of 12 patients.

  • ‡Duration of disease at the time of bone marrow sampling based on subjective onset of symptoms.

  • BTU, Bühlmann titre units; n.t., not tested.